Arsani William - 21 Mar 2022 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Director
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Issuer symbol
DSGN
Transactions as of
21 Mar 2022
Transactions value $
$474,680
Form type
4
Filing time
22 Mar 2022, 19:28:14 UTC
Previous filing
02 Sep 2021
Next filing
16 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Purchase $474,680 +25,000 +0.9% $18.99* 2,797,501 21 Mar 2022 By Logos Global Master Fund LP F2
holding DSGN Common Stock 1,217,627 21 Mar 2022 By Logos Opportunities Fund II, L.P. F1
holding DSGN Common Stock 2,032,501 21 Mar 2022 By Logos SPV 1 LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2 Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.